PM Beats Q2 on Smoke-Free Momentum, Holds Full-Year Guidance

Transcript intelligence

What changed

Versus Q1, Q2 saw organic revenue growth moderate from 9% to 8% YoY, while operating income growth accelerated to 11%. New developments this quarter include IQOS being named to Kantar's top 100 most valuable global brands for the first time, the launch of BONDS by IQOS in Poland, Czech Republic, and Morocco, and ZYN receiving MRTP (modified risk tobacco product) authorization in the U.S., enabling reduced-risk marketing claims. Capex outlook shifted to increasing as the company invests in U.S. production capacity. Management also highlighted an accelerated U.S. marketing push with the 'When it Clicks' campaign and expanded ZYN nicotine strengths (1.5 mg, 8 mg, and ZYN Ultra).

Guidance delta

Full-year 2026 guidance was maintained for the second consecutive quarter: 5-7% organic revenue growth, 7-9% operating income growth, and EPS of $8.26-$8.41. No upward revision despite the beat, suggesting management is building in a cushion for regulatory and macro risks, particularly Japan excise-tax hikes and European flavor bans.

Key takeaways

• Q2 EPS of $2.20 beat consensus of $2.05 by 7.3%; revenue of $11.19B exceeded estimates of $10.60B by 5.6%.
• Smoke-free products (IQOS, ZYN, VEEV) drove double-digit volume growth across multiple markets, reinforcing their role as the primary growth engine.
• Full-year guidance held at 5-7% revenue growth, 7-9% operating income growth, and EPS $8.26-$8.41 for the second straight quarter.
• ZYN received MRTP authorization in the U.S., enabling reduced-risk marketing claims - a significant regulatory milestone for the pouch business.
• Combustible sales outperformed expectations, supported by pricing power and emerging-market volume in Indonesia, Turkey, Mexico, and India.
• U.S. investment is accelerating with ZYN Ultra rollout, new nicotine strengths, and the 'When it Clicks' marketing campaign.

Management priorities

• Roll out IQOS ILUMA in the United States pending FDA approval.
• Expand ZYN Ultra and new low-nicotine (1.5 mg, 8 mg) variants.
• Execute the 'When it Clicks' marketing campaign to boost ZYN brand equity.
• Launch DELIA, LEVIA, VEEV One Plus, and BONDS extensions across markets.
• Increase U.S. production capacity and global distribution through higher capex.